Canopy Growth Corporation

Informe acción NasdaqGS:CGC

Capitalización de mercado: US$410.7m

Canopy Growth Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Canopy Growth ha aumentado sus beneficios a una tasa media anual de 26.3%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento anual de 9.7%. Los ingresos han ido disminuyendo a una tasa media de 17.9% al año.

Información clave

26.29%

Tasa de crecimiento de los beneficios

40.39%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals 5.95%
Tasa de crecimiento de los ingresos-17.94%
Rentabilidad financiera-43.17%
Margen neto-117.57%
Próxima actualización de resultados15 Jun 2026

Actualizaciones de resultados anteriores recientes

Recent updates

Seeking Alpha • Apr 23

Canopy Growth Rallies On Renewed Hope Of Cannabis Rescheduling

Summary Canopy Growth rallied yesterday on news that the Trump administration may reschedule cannabis soon. The entire cannabis sector experienced a rally over the day. The development does not tell us when it will happen nor how it will happen. The current rally may subside once there are no further developments. I continue my rating of a Hold. Read the full article on Seeking Alpha
Seeking Alpha • Apr 22

Canopy Growth: Zombie Financials As Delisting Threat Looms

Summary Canopy Growth is down substantially year-to-date as the company files to issue and sell $200 million more worth of its common shares. Dilution for the last 3 years is 177%. Free cash flow for CGC's most recent quarter remains negative, but like net income, the figure has seen some improvement over its year-ago figure. The company now barely sits above the $1 minimum listing price required by the NASDAQ. Read the full article on Seeking Alpha
Seeking Alpha • Mar 30

Cannabis Investors Should Sell Canopy Growth

Summary Canopy Growth's stock has plummeted over 99% from its peak, facing severe financial challenges, including significant debt and a massive increase in shares outstanding. Despite some potential for a rebound, the stock's valuation remains unattractive, with an enterprise value to projected adjusted EBITDA ratio of 85X for FY26. Better investment alternatives in the cannabis sector include Village Farms, Organigram, Tilray Brands, and Cronos Group, which offer superior valuations and operational performance. I am upgrading Canopy Growth stock to Sell from Strong Sell, but recommend exploring other cannabis stocks or ancillary companies like GrowGeneration for better opportunities. Read the full article on Seeking Alpha
Seeking Alpha • Feb 17

Canopy Growth: Q3 Earnings Shows Improvement But Cannabis Sector Remains Weak

Summary Canopy Growth recently reported improved Q3-2025 financial results. They expect continued growth across operating segments. The company's stock price is down 46% over the last twelve months. Investor sentiment continues to be weak on the cannabis sector. I continue my rating of a Hold. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Canopy Growth: Still A Disaster Heading Into Fiscal Q3 Results

Summary Canopy Growth Corporation is likely to report weak financials when reporting FQ3 results on February 7. The company struggles with low gross margins of 35% and continues to burn cash, while a peer's results support strong growth in the international medical cannabis business. The recent acquisitions of Acreage Holdings and Wana Brands may boost revenue, but the profit picture remains bleak, with a new CEO likely to restructure the business. Investors should be cautious; despite potential revenue growth, CGC stock's outlook hinges on improved margins and positive EBITDA, which remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Jan 22

Crashing Canopy Growth Is Still Not A Buy

Summary Canopy Growth's stock has plummeted over 90% in a decade, with further declines expected due to ongoing financial struggles and lack of U.S. market progress. Despite potential short-term gains from filling price gaps, Canopy Growth remains a Strong Sell due to its unprofitability and high debt levels. Constellation Brands is unlikely to buy Canopy Growth, given its previous failed investment and current financial structure. There are better investment opportunities in cannabis stocks, both in Canadian LPs like Organigram and Village Farms, and U.S. MSOs like Cresco Labs and Verano Holdings. Read the full article on Seeking Alpha
Seeking Alpha • Jan 11

Canopy Growth Remains Undervalued Amidst Cannabis Sector Uncertainty

Summary Canopy Growth is down 46% over the last twelve months and hit its 52-week low on Friday. The company recently reported in-line financial results and positive outlook. The cause of the downtrend concerns uncertainty around cannabis regulation in the US. The greater stock market is undergoing extreme volatility and the cannabis sector remains weak. I continue my previous rating of a Hold and believe markets will settle in February. Read the full article on Seeking Alpha
Seeking Alpha • Nov 10

Avoid Canopy Growth

Summary Canopy Growth's stock has significantly declined due to high debt, negative cash flow, and underwhelming financial performance, with a potential to drop to $1. The company's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Despite some improvement in adjusted EBITDA, Canopy Growth's valuation is too high compared to peers like Organigram and Cronos Group. Investors should consider better-valued and financially stronger cannabis stocks, as Canopy Growth's outlook remains bleak amidst ongoing financial struggles. Read the full article on Seeking Alpha
Seeking Alpha • Oct 05

Canopy Growth: Weak Fundamentals And Growth Acceleration Challenges

Summary Canopy Growth faces significant financial challenges, including a stressed balance sheet, high debt, and potential equity dilution, making it an unattractive investment. Despite initial excitement over potential cannabis rescheduling, the long-term impact on growth is uncertain, leading to renewed stock correction. Canopy's revenue is declining, with limited growth in international markets and reduced R&D and advertising expenses, further hindering growth prospects. Given the high valuation and ongoing regulatory headwinds, I recommend a "Sell" rating for Canopy Growth, favoring companies with stronger financial flexibility. Read the full article on Seeking Alpha
Seeking Alpha • Aug 27

Canopy Growth: Dilution, Executive Turnover, Cannabis Rescheduling Delay End High

Summary Canopy Growth Corporation stock rallied to $15 due to the DEA's proposal to reschedule cannabis, but this timeline has now been extended to 2025. CEO David Klein, who oversaw a 97% stock decline, is set to exit in March 2025 and has started selling shares. Klein's share sales were related to tax liabilities from vested restricted stock units, leaving him with 360,829 shares. Canopy Growth faces significant liquidity issues, holding $143 million in cash and short-term investments as of June 30, 2024. Read the full article on Seeking Alpha
Seeking Alpha • Jun 17

Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold)

Summary Canopy Growth recently reported improved financial performance for Q4-2024. Canopy USA has acquired US THC cannabis assets and plans to acquire more. The company expects an increase in demand for its international cannabis exports. Canopy Growth's stock price is down this month, but recently experienced a sustained rally on news of cannabis rescheduling in the US. I continue my previous rating of a Hold and unpack the risks. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Canopy Growth: Another Ugly Cannabis Report

Summary Canopy Growth Corporation's weak financial results have caused its stock to trade lower, leading to a loss of investor interest. The company reported another disastrous quarter with a weak adjusted gross margin, a large net loss, and negative adjusted EBITDA. The stock has an EV topping $1 billion, which is mismatched with the weak financial results. Read the full article on Seeking Alpha
Seeking Alpha • Apr 26

Canopy Growth Set For U.S. Cannabis Markets

Summary Canopy Growth has received shareholder approval for its plans to enter the US THC cannabis market. The company's recent Q3-2024 report shows ongoing financial recovery and success of the company's new right-sizing strategy. Canopy Growth's stock price has been on an ongoing uptrend, gaining 87% over the last three months. I change my previous rating of Canopy Growth from a buy to a hold. Read the full article on Seeking Alpha
Seeking Alpha • Mar 22

Canopy Growth Is Climbing, But It Won't Last

Summary Canopy Growth's shares have risen by 28% in the past month due to the potential rescheduling of cannabis in the U.S. However, the company is facing operational and financial challenges, with persistent cash flow difficulties and declining sales growth. The company's low valuation does not make it an attractive investment, and its future outlook remains bleak. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come

Summary Canopy Growth stock has fallen recently due to a dilutive secondary offering and ongoing financial troubles. With $411 million in net debt, I expect more dilution to come moving forward. Investors may be betting on a federal rescheduling of cannabis, but that is unlikely to benefit the company. I reiterate my strong sell rating for CGC stock due to the myriad of negative fundamental factors. Read the full article on Seeking Alpha
Seeking Alpha • Jan 29

Canopy Growth: Further Implosion Is Now A Matter Of When Not If

Summary Canopy Growth has reduced its free cash burn to CAD$67 million per quarter for an implied cash runway of five quarters against its current short-term liquidity position. Three institutional shareholders are looking to exit their positions, reducing their aggregate ownership from 13.4% to 2.5%. A high debt burden and elevated cash burn will drive continued near-term dilution for shareholders. Read the full article on Seeking Alpha
Seeking Alpha • Jan 14

Avoid Canopy Growth After Failed Equity Sale

Summary Canopy Growth's stock has declined 82.6% since I predicted a decline last January, much more than the market. The company's plan to transform into an American cannabis operator has not helped its stock performance. The recent decline in stock price was due to an equity offering announced by Canopy Growth early in the week. After the close on Friday, though, the deal was cancelled. Canopy Growth should be trading 50% lower. Read the full article on Seeking Alpha

Desglose de ingresos y gastos

Cómo gana y gasta dinero Canopy Growth. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:CGC Ingresos, gastos y beneficios (CAD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 25278-3271220
30 Sep 25279-3871310
30 Jun 25275-5161370
31 Mar 25269-6041460
31 Dec 24277-4771790
30 Sep 24280-5861890
30 Jun 24287-6021960
31 Mar 24297-4842090
31 Dec 23293-9992320
30 Sep 23299-9912670
30 Jun 23317-1,0253080
31 Mar 23333-3,0793350
31 Dec 22367-3,0514010
30 Sep 22423-2,9384450
30 Jun 22466-2,7665170
31 Mar 22476-2554940
31 Dec 21557-4285880
30 Sep 21569-1,2236160
30 Jun 21572-1,2446190
31 Mar 21547-1,7456640
31 Dec 20506-2,3487650
30 Sep 20477-1,5358430
30 Jun 20419-1,2449380
31 Mar 20399-1,3219930
31 Dec 19385-415961-5
30 Sep 19344-2568810
30 Jun 19291-8327940
31 Mar 19226-7366420
31 Dec 18155-3984704
30 Sep 1894-464350-1
30 Jun 1888-1481990
31 Mar 1878-671490
31 Dec 1770-21950
30 Sep 1758-19661
30 Jun 1749-13501
31 Mar 1740-8391
31 Dec 1630-1292
30 Sep 1624-7251
30 Jun 1618-8211
31 Mar 1613-3171
31 Dec 1580130
30 Sep 1561110
30 Jun 153-5100

Ingresos de calidad: CGC actualmente no es rentable.

Margen de beneficios creciente: CGC actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CGC no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 26.3% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CGC en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CGC no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (-5%).

Rentabilidad financiera

Alta ROE: CGC tiene una rentabilidad financiera negativa (-43.17%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/22 12:34
Precio de las acciones al final del día2026/05/22 00:00
Beneficios2025/12/31
Ingresos anuales2025/03/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Canopy Growth Corporation está cubierta por 23 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Cormark
Jesse PytlakATB Cormark Historical (Cormark Securities)